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Abstract 22 
In this study, we investigated the effects of oral treatments of E. multilocularis infected mice 23 
with the anti-malarial drug mefloquine, and identified proteins that bind to mefloquine in 24 
parasite extracts and human cells by affinity chromatography. In a pilot experiment, 25 
mefloquine treatment was applied 5 days per week and intensified by stepwise increasing the 26 
dosage from 12.5mg/kg to 200mg/kg during 4 weeks followed by treatments of 100mg/kg 27 
during the last 7 weeks. This resulted in a highly significant reduction of parasite weight in 28 
mefloquine-treated mice compared to mock-treated mice, but the reduction was significantly 29 
less efficacious as compared to the standard treatment regimen with albendazole. In a second 30 
experiment, mefloquine was orally applied in three different treatment groups at dosages of 31 
25, 50 or 100mg/kg, but only twice a week, for a period of 12 weeks. Treatment at 100mg/kg 32 
had a profound impact on the parasite, similar to albendazole treatment at 200mg/kg/day (5 33 
days/week for 12 weeks). No adverse side effects were noted. In order to identify proteins in 34 
E. multilocularis metacestodes that physically interact with mefloquine, we performed affinity 35 
chromatography of metacestode extracts on mefloquine coupled to epoxy-activated sepharose, 36 
followed by SDS-PAGE and in-gel digestion/LC-MS/MS. This resulted in the identification 37 
of E. multilocularis ferritin and cystatin as mefloquine-binding proteins. In contrast, when 38 
human cells were exposed to mefloquine-affinity chromatography, nicotinamide 39 
phosphoribosyl transferase was identified as a mefloquine-binding protein. This shows that 40 
mefloquine interacts with different proteins in parasites and human cells. 41 
 42 
 43 
 44 
45 
3 
INTRODUCTION 46 
The parasite Echinococcus multilocularis is an endoparasitic flatworm of the family 47 
Taeniidae. The life cycle of E. multilocularis is based on a predator-prey relationship. The 48 
definitive hosts are wild carnivores such as the red fox (Vulpes vulpes) and the arctic fox 49 
(Alopex lagopus), but the tapeworm also infects, and develops within the intestine of, 50 
domestic dogs and cats, increasing the infection pressure for humans [1, 2]. The definitive 51 
hosts shed eggs, which contain a first larval stage, the oncosphere. When taken up orally, 52 
oncospheres hatch as they reach the intestine, penetrate the intestinal wall and use the blood 53 
and lymphatic system for dissemination. They typically invade the liver, where they develop 54 
into the the metacestode stage, which causes human alveolar echinococcosis (AE). AE is 55 
distributed in the Northern hemisphere, the endemic areas stretching from Northern America 56 
through Central and Eastern Europe to Central and East Asia including Northern parts of 57 
Japan [1]. The increase in the urban fox populations in Central Europe, together with the high 58 
prevalence rate of E. multilocularis in foxes, has resulted in an increased environmental 59 
contamination with Echinococcus eggs, and as a consequence, this has led to an increased risk 60 
of transmission to humans [2]. 61 
Human AE manifests itself by tumor-like, infiltrative growth of metacestodes mainly in the 62 
liver, but other organs might also be affected. AE is often compared with a slow-growing 63 
liver cancer and if untreated the disease is usually lethal. The current strategy for treatment 64 
consists of surgical measures complemented by chemotherapy with mebendazole (MBZ) or 65 
albendazole (ABZ)). In inoperable cases, chemotherapy has proven to inhibit parasite 66 
proliferation acting parasitostatic, but benzimidazoles act rarely curative, resulting in life-long 67 
duration of treatment, high costs and elevated risk of side effects [3]. However, 68 
benzimidazoles have prolonged the average life expectancy of European patients at diagnosis 69 
from 3 to 20 years [3]. Nevertheless, alternative options for chemotherapy with parasiticidal 70 
activity are needed [4]. 71 
4 
Mefloquine (MEF) is a synthetic analogue of quinine commonly used in the treatment and 72 
prophylaxis of chloroquine-resistant Plasmodium falciparum malaria [5, 6]. The mechanism 73 
of action of MEF against Plasmodium species has not been completely elucidated, but several 74 
investigations indicated a disturbance of haemoglobin metabolism, followed by the formation 75 
of an insoluble polymer, hemozoin, causing parasite death [5]. It is not known whether a 76 
hemozoin-related mode of action is relevant for the anti-echinococcal activity of mefloquine 77 
in vitro.  78 
MEF also exhibited considerable efficacy against other helminths, such as Schistosoma 79 
mansoni, S. japonicum, Opisthorchis viverrini, Brugia patei and B. malayi [6-8]. We have 80 
earlier demonstrated the efficacy of MEF against AE in experimentally infected mice when 81 
the drug was applied intraperitoneally, but not when applied orally [9]. In this study we 82 
present two distinct oral MEF treatment protocols in E. multilocularis infected mice, and 83 
show that MEF treatment, when applied orally as a suspension in honey at a dosage of 84 
100mg/kg twice a week, exhibits anti-echinococcal activity comparable to ABZ applied orally 85 
at 200mg/kg/day. We also show that (i) the iron-binding protein ferritin, and (ii) cystatin, a 86 
potential immune-modulator in parasite infections, bind to MEF, and thus possibly could be 87 
targeted by MEF in E. multilocularis metacestodes. In contrast, MEF-affinity chromatography 88 
of the human cancer cell line Caco2 results in binding of the enzyme nicotinamide 89 
phosphoribosyl transferase (NPT). 90 
 91 
MATERIALS AND METHODS 92 
 93 
Biochemicals and compounds. If not stated otherwise, all culture media and reagents were 94 
purchased from Gibco-BRL (Zürich, Switzerland) and biochemical reagents were from Sigma 95 
(St. Louis, Mo, USA). MEF was kindly supplied by Mepha Pharma AG (Aesch BL, 96 
Switzerland). 97 
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 98 
In vitro culture. The culture of E. multilocularis (isolate H95) was carried out as previously 99 
described [10]. The human colon carcinoma cell line Caco2 was maintained as previously 100 
described by Müller et al [11]. 101 
 102 
Experimental infection of mice and treatments with MEF and ABZ. Female Balb/c mice 103 
(age 9 weeks; average body weight average of 25g) were housed in a temperature-controlled 104 
daylight/night cycle room with food and water ad libitum. Experiments were carried out 105 
according to the Swiss Federal Animal Welfare regulations (TschV, SR 455) under the 106 
licence number BE103/11. Metacestode solid fraction was obtained by extensive washing of 107 
in vitro cultured parasites with PBS, breaking the vesicles mechanically, followed by 108 
centrifugation [10]. The animals were randomly divided into experimental groups, and were 109 
then infected by intraperitoneal injection of 100μL of metacestode solid fraction in 100μL 110 
PBS. 111 
The pilot experiment was performed with 15 mice, which were divided into 3 groups of 5 112 
animals each. Compounds were formulated in 1% carboxymethylcellulose (CMC) at 113 
concentrations indicated below. Starting at 6 weeks post infection, mice were treated by 114 
gavage for a period of 11 weeks with either 100µL honey/CMC 1% (control group), 100µL 115 
ABZ (200mg/kg in honey/CMC 1%; ABZ group) or 100µL MEF at different concentrations 116 
(from 12.5mg/kg up to 200mg/kg in honey/CMC 1%; MEF group), basically 5 days per week 117 
and according to the treatment regimen depicted in Supplementary Figure 1. During the 118 
treatment, animals were carefully monitored and checked for clinical signs of impaired health 119 
such as weight loss, ruffled coat, hunched back, and changes in behavior (inactivity, 120 
nervousness), and the treatment regimen was adjusted accordingly. At the end of the 121 
treatment period of 11 weeks, the animals were euthanized, and after necropsy the parasite 122 
tissue was collected and the parasite weight measured. After pressing this material through a 123 
6 
metal tea strainer, 100µL of the resulting metacestode solution were re-injected into 2 mice 124 
per group to observe whether the parasite was still viable and regrowing.  125 
Experiment 2 was performed with 39 mice of 9 weeks age, which were divided into 4 126 
treatment groups of 8 animals each, and a control group of 7 animals. Starting at 6 weeks 127 
post-infection, mice were treated as follows: the control group received 100µL 128 
honey/CMC1%; the ABZ group received ABZ (200mg/kg) emulsified in honey/CMC1%; the 129 
MEF treatment groups were treated by gavage of MEF emulsified in honey/CMC 1% at 130 
25mg/kg, 50mg/kg and 100mg/kg, respectively. The treatments were performed for a period 131 
of 12 weeks on 5 days/week for the ABZ-treated group and twice weekly for the MEF-treated 132 
groups. On those days where no MEF, but ABZ, was administered, mice from the MEF 133 
groups received honey/CMC1%. At the end of the study the animals were euthanized, and 134 
after necropsy the parasite tissue was collected and the parasite weight measured. The 135 
parasiticidal activity was assessed by in vitro cultivation of resected parasite-material. 136 
The data was analyzed by use of the software R version 3.0.1. Upon removal of Grubbs 137 
outliers, data was analyzed by one-way ANOVA Bonferroni-adjusted P values calculated by 138 
Pairwise T-Test. Data was visualized by boxplot in Microsoft Office Excel 2010.  139 
 140 
Coupling of MEF to epoxy-activated sepharose matrix. MEF was coupled to epoxy-141 
activated sepharose matrix with a 12C spacer [11]. For this, 0.5g sepharose was extensively 142 
washed with distilled water and sedimented, followed by a two-step wash with coupling 143 
buffer (100mM NaHCO3, pH 9.5). 20mg of MEF-HCl, solubilised in 1 ml DMSO, was added 144 
to 1ml of the washed epoxy-sepharose matrix and incubated for 72h on a a slow horizontal 145 
shaker at 37°C for 3 days in order to allow coupling to the epoxy-group. The resulting matrix 146 
was then transferred to a chromatography column (Novagen, Merck, Darmstadt, Germany) 147 
and washed with 20ml coupling buffer, followed by 1M ethanolamine pH 9.5 for 4h at room 148 
temperature in the absence of light, in order to block residual groups. Subsequently, the 149 
7 
column was extensively washed with PBS and PBS/DMSO (1:2) in order to remove unbound 150 
mefloquine. In additon to the MEF-sepharose column a mock-column was prepared 151 
containing epoxy-sepharose treated identically as described above but in the absence of MEF. 152 
The columns were stored in PBS containing 0.02% NaN3 at 4°C. 153 
 154 
Tandem-affinity chromatography of metacestode extracts and Caco2 cell lysates on 155 
epoxy-sepharose and MEF-epoxy-sepharose columns.  Metacestode extracts were prepared 156 
from in vitro cultured parasites maintained under axenic conditions (i.e. in culture medium, 157 
but without rat hepatoma cells) and without FCS for 72h. After extensive washing with PBS, 158 
parasites were mechanically disrupted in PBS, centrifuged, and the pellet was resuspended in 159 
PBS containing Triton X-100 (0.1 %), 100µL Halt protease inhibitor (Thermo Fisher 160 
Scientific, Rockford, IL, USA) and 100 µL EDTA, and incubated at room temperature for 10 161 
min. Following centrifugation at 4696 x g for 5min at room temperature. The supernatant 162 
(12ml) was collected and used for tandem-affinity chromatography. Cell free extracts from 163 
human Caco2 cells were prepared as described [11]. Extracts were first passed over the 164 
sepharose column without compound (mock column) at a flow rate of 0.2 ml/min, and the 165 
flow-through was collected, and then further loaded onto the MEF-sepharose matrix. Prior to 166 
elution, columns were washed with 8 column volumes of PBS. Elutions of both columns were 167 
done with PBS containing 10 mM MEF-HCl from a 100mM stock in DMSO. A second 168 
elution step was performed by applying 4ml of a low pH-buffer (100 mM glycine, pH 2.9).  169 
Fractions of 4ml volume each were collected and precipitated overnight with 80% acetone at -170 
20°C. The precipitates were solubilized in 30µl Laemmli buffer and separated by 10% SDS-171 
PAGE using a Hoefer minigel 250 apparatus (Amersham, GE Healthcare, Little Chalfont, 172 
United Kingdom). Proteins were visualized by silver staining [12]. For mass spectrometry 173 
(MS) analysis, colloidal Coomassie staining was applied overnight, and selected protein 174 
bands were cut out with a clean scalpel, placed in Eppendorf tubes containing ethanol/distilled 175 
8 
water (1:4) and stored at 4°C. The in-gel digestion/LC-MS/MS analysis was performed by the 176 
Mass Spectrometry and Proteomics Facility at the Department of Clinical Research of the 177 
University of Bern. The sequences obtained were blasted against standard protein databases 178 
for eukaryotes and against the database for Echinococcus multilocularis 179 
(http://www.genedb.org/Homepage/Emultilocularis). 180 
 181 
Cytotoxicity assays. Toxicity of MEF on Caco2 cells was determined and IC50 values were 182 
calculated as previously described [11].  183 
 184 
 185 
RESULTS  186 
 187 
Oral application of MEF acts against E. multilocularis metacestodes in experimentally 188 
infected mice. Initial experiments carried out earlier had shown that MEF treatment of E. 189 
multilocularis-infected mice at25 mg/kg twice a week by oral route did not lead to a reduction 190 
in parasite weight, while intraperitoneal application had a profound effect [9].  191 
In a pilot experiment, we applied an intensified MEF treatment protocol characterized by a 192 
stepwise increase of drug concentration (see Supplementary Figure 1). During an initial 193 
period of 9 days, 12.5mg/kg of MEF was applied 5 times, followed by 2 days without 194 
treatment and another 2 consecutive days of MEF treatment (see Supplementary Figure 1). No 195 
adverse effects were noted, thus the dose was increased to 50mg/kg for another 3, 5 and 4 196 
days treatments, all within a 16 days period (see Supplementary Figure 1). Again, no adverse 197 
effects or behavioural changes were noted. The dose was increased to 100mg/kg for 2 days, 198 
and then increased to 200mg/kg for another 2 days, which then resulted in rapid weight loss 199 
(see Supplementary Figure 1) and ruffled coats in three of five mice, and one mouse died on 200 
day 30. Subsequently the MEF dosage was kept at 100mg/kg, and was applied as such 31 201 
9 
times during the residual 48 days, during which the mice recovered body weight again and did 202 
not show further side effects. No changes in body weight or any other adverse effects were 203 
noted in ABZ treated mice. At the end of the 11 week experimental treatment, mice had 204 
ingested a total of 4.0875g/kg of MEF per mouse or 10.8g/kg of ABZ (ratio MEF : ABZ = 205 
1:2.45), respectively. Measurement of parasite weights at the end of the treatment period of 206 
11 weeks showed there was a significantly beneficial effect of MEF treatment compared to 207 
the non-treated control group (p=0.0016, Fig. 1A). However, the intensified MEF treatment 208 
was not as efficacious as daily ABZ treatment, as the parasite weights in the MEF treatment 209 
group were significantly higher compared to the ABZ treatment group (p = 0.0495) (Fig. 1A). 210 
ABZ treatment led to a highly significant reduction of cyst weight (p=7.4E-05). Drug 211 
treatments did not act parasiticidal, since reinfection with cyst material of two mice per group 212 
resulted in parasite-regrowth in all cases (data not shown). 213 
In experiment 2, MEF was applied to mice orally by feeding of a MEF-honey suspension, at 214 
drug concentrations of 25 mg/kg, 50mg/kg or 100mg/kg only twice a week. As reference 215 
control, mice were treated with ABZ (200mg/kg on 5 days per week). No adverse side effects, 216 
no weight loss and no behavioural changes could be detected in any of the animals during the 217 
time of drug treatment. During these 12 weeks, mice treated with 100mg/kg of MEF twice per 218 
week ingested a total of 2.4g/kg of MEF, and mice treated with ABZ were given a total of 12 219 
g/kg of ABZ (MEF : ABZ = 1:5). Measurement of the parasite burden at the end of the 220 
treatment period of 12 weeks showed that oral MEF treatment at 100mg/kg twice a week was 221 
as efficacious as daily ABZ treatment (200mg/kg/day) (Fig. 1B). The reduction in parasite 222 
burden was a significant in the ABZ-treated group (p=0.018) and in the MEF (100mg/kg) 223 
treated mice (p=0.018), while MEF treatment at lower doses (25 and 50mg/kg) showed a non-224 
significant reduction. None of these drug treatments acted parasiticidal, since in vitro culture 225 
of parasite material from all the treatment groups resulted in regrowth of metacestode 226 
vesicles. 227 
10 
 228 
Epoxy-sepharose-immoblilized MEF binds E. multilocularis ferritin and cystatin. In 229 
order to identify proteins that interact with MEF, E. multilocularis metacestode fractions were 230 
exposed to sepharose-bound MEF. The fractions eluted from the mock-sepharose and the 231 
MEF-sepharose columns were analyzed by SDS-PAGE and silver staining (Fig. 2). After 232 
loading E. multilocularis extract onto the mock-sepharose and subsequent MEF affinity 233 
chromatography of the flow-through, the columns were washed with MEF-containing elution 234 
buffer and subsequently with low pH buffer. As seen in Fig. 2, washing of the mock-235 
sepharose column with MEF-containing elution buffer did not result in removal of any 236 
proteins. The elution with low pH-buffer revealed that considerable amounts of E. 237 
multilocularis proteins bound to the sepharose matrix and were released again at low pH. 238 
MEF-sepharose affinity chromatography of the mock-sepharose-flow-through fraction 239 
yielded a major double-protein band of around 20kDa eluting with MEF-containing buffer. 240 
Subsequent washing with low-pH buffer did not result in further release of proteins (Fig. 2). 241 
The two bands of the MEF elution (indicated with arrows as 1 and 2, Fig. 2) were cut out and 242 
analysed by in-gel digestion/LC-MS/MS. Both protein bands were identified as ferritin and 243 
cystatin from E. multilocularis (Table 1; EmuJ_000382200.1 and EmuJ_000849600.1). 244 
 245 
Epoxy-sepharose-immoblilized MEF binds to human nicotinamide-phosphoribosyl-246 
transferase (NAPRT) 247 
Human cancer cells have been shown to be highly susceptible to antimalarials including MEF 248 
[13]. The susceptibility of the human colon cancer cell line Caco2 against MEF was assessed 249 
in vitro. The IC50 for non-confluent Caco2 cells was 0.7±0.1µM, and confluent cells exhibited 250 
an IC50 of 3.6±0.7µM. MEF binding proteins in human cells were identified using the 251 
identical approach as for E. multilocularis metacestodes, resulting in the elution of a single 252 
major band of approximately 50kDa. Subsequent elutions with with low-pH buffer were 253 
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devoid of major bands (Fig. 3). The 50kDa band was subjected to analysis by mass 254 
spectrometry and identified as the 491 amino acid protein nicotinamide-phosphoribosyl-255 
transferase (NAPRT; P43490). 256 
 257 
DISCUSSION 258 
 259 
As the pilot study showed, a stepwise increase of oral MEF input was significantly effective, 260 
but had detrimental effects, resulting in a lower efficacy of MEF compared to ABZ, and 261 
obvious adverse side effects once higher concentrations than 100mg/kg were applied. 262 
The second study demonstrates that oral application of mefloquine at 100mg/kg twice a week 263 
for 12 weeks in experimentally infected mice acts against E. multilocularis metacestodes in a 264 
similar manner as oral application of albendazole (200mg/kg/ on 5 days per week). 265 
Mefloquine applied at 25mg/kg or 50mg/kg was ineffective, confirming results from earlier 266 
studies [9]. At the lower concentrations the bioavailability of MEF was probably too low to 267 
elicit a therapeutically active serum level, while an increased MEF input resulted in serum 268 
levels that induced toxicity. For comparison, high single oral MEF doses of 200 to 400mg/kg 269 
were necessary to achieve significant worm burden reductions in S. mansoni- and S. 270 
japonicum-infected mice. However, for extended treatments (as they would be anticipated in 271 
AE patients), the application of MEF could be problematic. Daily doses above 12.5mg/kg 272 
have been reported to cause epilepsy or impairment of motor performance, and increased 273 
lethality was observed in mice at dosages of 30mg/kg and more [14-18]. Despite of the 274 
reported adverse effects of MEF when applied in high doses [18], no adverse effects were 275 
observed in the behavior or overall health of the animals throughout the treatment phase in 276 
experiment 2, most likely due to the fact that treatments were restricted to twice a week. In 277 
any case, this study shows the critical role of dosage to achieve anti-parasitic activity without 278 
causing adverse effects. Further it has to be highlighted that unlike shown in a previous in 279 
12 
vitro study [9], in vivo MEF treatment did not kill the parasite completely. Full parasiticidal 280 
activity, and especially toxic activity against E. multilocularis stem cells, would be necessary 281 
to completely kill the parasite and avoid the necessity of life-long drug uptake [19]. 282 
Research on novel compounds for the treatment of secondary AE in mice should focus on 283 
drugs or drug classes that are already marketed and/or in clinical development, and these are 284 
preferably cancer drugs or broad-spectrum anti-parasitic compounds. In this respect, MEF is 285 
commercially available, FDA-approved, and has been extensively characterized in terms of 286 
bioavailability, pharmacokinetics, and toxicity. However, the adverse effects reported upon 287 
the uptake of MEF are a problematic issue. The drug is known to cause neurotoxicity, and 288 
neuropsychiatric effects have been reported. Thus, it would be important to further investigate 289 
derivatives of MEF, and identify those compounds with similar anti-parasitic activity but with 290 
an impaired ability to pass through the blood-brain barrier. In addition, it has been shown that 291 
MEF is metabolized only slowly, with a plasma half-life in humans of 2-4 weeks, and 292 
metabolization occurs in the liver. During long-term treatments, as they would be anticipated 293 
in human patients suffering from AE, which represents mainly a liver-associated disease, this 294 
could cause significant adverse effects. 295 
 296 
The interaction of E. multilocularis ferritin and cystatin with MEF by affinity 297 
chromatography could indicate a possible anti-echinococcal mechanism of action for the drug. 298 
Both proteins were detected in two bands that migrated closely together on SDS-PAGE. 299 
Ferritin is an important intracellular iron-storage protein, generally composed of 24 subunits 300 
of around 20kDa and these 24 subunits are made up by ferritin heavy and light chains [20]. In 301 
E. multilocularis there has only one gene been identified for ferritin. Invertebrate ferritins 302 
show greater similarity towards the vertebrate heavy chains than towards the light chains, and 303 
ferritin heavy and light chains have been identified in nematodes and trematodes [21]. Thus, 304 
possibly the light chain homologue has not been identified in the E. multilocularis genome so 305 
13 
far due to more pronounced sequence divergence. Further, E. multilocularis ferritin has a 306 
predicted size of 19.8kDa that is in accordance with the apparent molecular weight of the 307 
protein bands on the silver stained gel. Ferritin is responsible for the maintenance and 308 
transport of iron in a non-toxic form In addition, ferritin heavy chain possesses ferroxidase 309 
activity, converting Fe
2+
 to Fe
3+
. Fe
2+
 can interact with hydrogen peroxide, resulting in highly 310 
damaging hydroxyl radical formation [20]. Thus, we propose that there could be a link 311 
between iron metabolism of the parasite and the mode of action of MEF in E. multilocularis 312 
metacestodes. Plasmodium species use haemoglobin, an extracellular Fe-containing protein of 313 
vertebrates, as a nutrient source. Interestingly, the mode of action of MEF in plasmodia is 314 
linked to binding of the heme part of haemoglobin [5], which implies that the Fe-containing 315 
residue is crucial both in plasmodia and Echinococcus for the action of MEF. 316 
Cystatins are inhibitors of cysteine proteases of the C1 family. However, in the field of 317 
parasitology, cystatins are given special attention, because they regulate the activity of 318 
proteases involved in parasite migration, and they are immunomodulators of parasite 319 
infections [22]. Interestingly, in the trematode Schistosoma mansoni cystatin is involved in 320 
the regulation of haemoglobin degradation [23]. The E. multilocularis cystatin has a predicted 321 
molecular weight of 30.9kDa. This is not in accordance with the apparent molecular weight of 322 
the protein bands on gel of about 20kDa, thus the detected band could have resulted from 323 
protein degradation. 324 
One has to keep in mind, however, that MEF may bind to proteins that do not contain iron. In 325 
Schistosoma, enolase has been identified as a MEF binding protein [24]. Here, we show that 326 
human NAPRT binds to MEF. NAPRT, also known as visfatin, is a key enzyme in the NAD 327 
salvage pathway and acts as an immunoregulatory cytokine [25]. By activating sirtuin, 328 
NAPRT promotes cell longevity [26] and has neuroprotective effects [27]. Conversely, 329 
inhibition of NAPRT induces apoptosis rendering this protein an interesting target for the 330 
development of anti-tumor agents [28]. 331 
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MEF is not the only anti-malarial exhibiting anti-echinococcal activity. For artemisinin 332 
derivatives such as antimalarial peroxides it has been shown that peroxide-bond reduction by 333 
hemoglobin-derived Fe
2+
 produces short-lived alkoxy radicals, which quickly rearrange to a 334 
carbon-centred radical that alkylates heme, forming heme-drug adducts [29]. Similar to 335 
mefloquine, these artemisinins also have a high activity against schistosomes, which like 336 
plasmodia, digest haemoglobin, in this instance by ingestion of erythrocytes [30]. The anti-337 
schistosomal properties of MEF have also been established, and the presence of haemin was 338 
shown to enhance the treatment efficacy [6, 30]. However, MEF-affinity chromatography of 339 
Schistosoma mansoni schistosomula had revealed that the glycolytic enzyme enolase binds to 340 
the drug [24], and this study had demonstrated a potential role of MEF as an inhibitor of 341 
glycolysis in stages where heme degradation was not relevant.  342 
In conclusion, MEF is effective in the treatment of AE when administered orally at high 343 
doses, but only twice a week. Moreover, the drug presents the advantages of being 344 
commercially available and currently used for the prophylaxis and treatment of malaria. 345 
Despite much discussion, the mechanism of action of MEF is not yet clarified for 346 
Plasmodium species. For E. multilocularis, we have identified ferritin and cystatin as two 347 
MEF-binding proteins, which are clearly different from NAPRT pulled out from human cell 348 
extracts, and their role as drug targets for MEF in these parasites will be further evaluated in 349 
future studies.  350 
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Figure legends 437 
 438 
Figure 1. Effects of oral treatments of E. multilocularis infected mice in terms of 439 
recovered parasite weight. In the pilot experiment (A), oral application of albendazole 440 
(ABZ) was compared with mefloquine treatment (MEF) for a period of 11 weeks at dosages 441 
as indicated in Supplementary Fig. 1. The control group received oral treatment with solvent 442 
only (honey/CMC 1%). Note that the differences in parasite weights between the ABZ, MEF 443 
and control group are all significantly different from each other. In experiment 2 (B) mice 444 
were treated for a period of 12 weeks with either honey/CMC 1% (control), albendazole 445 
(ABZ; 200 mg/kg daily on 5 days per week) or mefloquine (MEF; 25, 50 or 100 mg/kg twice 446 
per week). Note the significantly reduced parasite weight in the ABZ and MEF (100mg/kg) 447 
group, while MEF was ineffective at 25 and 50 mg/kg. For statistical analysis, Grubbs outliers 448 
were removed, and further testing performed with ANOVA and Bonferroni-adjusted P values 449 
calculated by Pairwise T-Test. 450 
 451 
Figure 2. SDS-PAGE visualization of proteins from soluble E. multilocularis metacestode 452 
extract eluted after affinity chromatography with mefloquine bound to epoxy-activated 453 
sepharose. Silver stained gel showing fractions eluted from the unloaded epoxy-sepharose 454 
column (Mock column) and the subsequent mefloquine column. Pre-mef = flow-through 455 
fraction obtained prior to mefloquine elution; mef = fraction eluted with excess mefloquine; 456 
pre-pH = fraction obtained prior to pH-shift elution; pH = fractions eluted with low-pH 457 
buffer. The two bands eluted with excess mefloquine (indicated by arrows 1 and 2) were cut 458 
out and subjected to LC-MS/MS analysis.  459 
 460 
Figure 3. SDS-PAGE visualization of proteins from soluble human colon cancer (Caco2) 461 
cell extract eluted after affinity chromatography with mefloquine bound to epoxy-462 
activated sepharose. Silver stained gel showing cell extract (CE) loaded onto the columns, 463 
flow through (FT) and wash fraction (pre-mef = flow-through fraction obtained prior to 464 
mefloquine elution. mef = fraction eluted with excess mefloquine; pH1 and pH2 = fractions 465 
eluted with low-pH buffer. The band eluted with excess mefloquine (indicated by arrow) was 466 
cut out and subjected to LC-MS/MS analysis.  467 
 468 
 469 
 470 
 471 
18 
Supplementary Figure 1. For the pilot experiment, the treatment regimen (A) and the 472 
development of mean body weights measured during treatments (B) are presented. 473 
Albendazole (ABZ) dosage was kept continuously at 200 mg/kg per application, while the 474 
dosages for mefloquine (MEF) varied. Monitoring of the mean body weight during the 475 
treatments shows a marginal impact of ABZ, while for MEF the high dosage of 200 mg/kg 476 
twice resulted in weight loss and subsequent death of one animal on day 30 (arrow). The 477 
remaining mice recovered when MEF-treatment was continued at lower dosage (31 x 100 478 
mg/kg during the next 48 days) and these mice finally achieved a similar body weight as 479 
ABZ-treated mice. 480 
 481 
 482 
 483 
 484 
 485 
AC Description PMSS 
band 1 
PMSS 
band 2 
Protein 
score 
Cov 
% 
#PSMs #Peptides 
EmuJ_000382200.1 ferritin 3875.722 3655.734 1758.516 93.68 1111 81 
EmuJ_000849600.1 proteinase inhibitor I25, cystatin 31.046 5.346 1367.22 77.09 386 64 
EmuJ_000684200.1 Lipid transport protein, N terminal  5.922 60.982 2.21 7 7 
EmuJ_000720500.1 ATP synthase subunit alpha, 
mitochondrial 
 5.269 17.903 4.2 2 2 
 486 
 487 
Table 1. Analysis of in-gel digestion LC-MS/MS of two bands (1 and 2), the two 488 
mefloquine-binding proteins eluted by affinity chromatography using mefloquine-489 
epoxy-sepharose. Represented are the accession numbers (AC) of the identified proteins in 490 
the database http://www.genedb.org/Homepage/Emultilocularis; their description; the PMSS 491 
values that are the sum of z-scores of all peptides of a protein, thus representing a 492 
semiquantitative measure of the abundance of the respective proteins; the protein score; the 493 
percentage of coverage (cov %) of each protein; the number peptide scan matches (PSMs); 494 
the number of peptides. 495 
 496 
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